A category of diabetes drugs, which embrace the best-selling drug Ozempic, are related to a lowered danger of sure obesity-related cancers, in keeping with a examine launched Friday.
Revealed within the journal JAMA, the examine in contrast sufferers with Kind 2 diabetes who had been handled with insulin versus sufferers who got a category of drug often called GLP-1 agonists, like Ozempic, between 2005 and 2018.
The researchers discovered that the sufferers who acquired GLP-1 agonists had a considerably decrease danger of growing 10 out of 13 cancers studied, together with kidney, pancreatic, esophageal, ovarian, liver and colorectal most cancers.
Among the many cancers which noticed no vital change in danger had been thyroid most cancers and breast most cancers in postmenopausal girls.
“Weight problems is well-known to be related to no less than 13 most cancers varieties,” examine writer Rong Xu mentioned in an electronic mail to AFP.
“Our examine supplies proof that GLP-1RAs maintain promise in breaking the hyperlink between weight problems and most cancers,” Xu mentioned.
Among the many medication studied had been semaglutide – commercially offered as Ozempic – in addition to liraglutide and others. Ozempic was permitted in the USA in 2017.
GLP-1 agonists have been round for about 20 years, however a brand new era of those medication, amongst them Ozempic, has been popularized for his or her extra vital weight reduction results.
Xu recommended that the protecting advantages demonstrated within the examine could encourage docs to prescribe GLP-1 therapies for diabetes sufferers as an alternative of different medicines like insulin.© Agence France-Presse